Modality
Vaccine
MOA
CGRPant
Target
FGFR
Pathway
T-cell
RSV
Development Pipeline
Preclinical
~Sep 2023
→ ~Dec 2024
Phase 1
Mar 2025
→ Jul 2025
Phase 1Current
NCT07258454
1,288 pts·RSV
2025-03→2025-07·Not yet recruiting
1,288 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-07-079mo agoInterim· RSV
Trial Timeline
Q2Q3
P1
Not yet…
Catalysts
Interim
2025-07-07 · 9mo ago
RSV
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07258454 | Phase 1 | RSV | Not yet recr... | 1288 | SRI-4 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Terafutibatinib | Pfizer | Phase 1/2 | CD38 | |
| Sotovorutinib | Pfizer | Approved | Aβ | |
| LLY-1592 | Eli Lilly | NDA/BLA | FGFR | |
| Doxarasimod | Merck & Co | NDA/BLA | FGFR | |
| ABB-3060 | AbbVie | Phase 2 | LAG-3 | |
| AZN-7403 | AstraZeneca | Phase 2/3 | FGFR | |
| GIL-6239 | Gilead Sciences | Phase 2 | TNFα | |
| Cevitinib | Regeneron | Phase 3 | FGFR | |
| Tezecilimab | Regeneron | Approved | IL-23 | |
| INC-2432 | Incyte | Phase 2 | CD47 |